<DOC>
	<DOC>NCT01041573</DOC>
	<brief_summary>The primary objective is to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51 administered in two doses in a 28 days interval up to Month 7 after the first IC51 vaccination in a pediatric population from endemic regions.</brief_summary>
	<brief_title>Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis, Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male or female healthy children and adolescents aged &gt; 2 months to &lt; 18 years at the time of first vaccination. Written informed consent by the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable. Female subjects: either no childbearing potential or negative pregnancy test, for females after menarche willingness to practice a reliable method of contraception. Clinical manifestation of Japanese Encephalitis History of Flavivirus vaccination (including any investigational vaccines) History of vaccination with HAVRIX®720 and/or Prevnar® History of immunodeficiency or immunosuppressive therapy Known HIV, HBV or HCV infection History of hypersensitivity reactions to other vaccines Acute febrile infection at each visit during which the subject receives a vaccination Active or passive immunization within 2 weeks prior to the first IC51 vaccination and up to the second IC51 vaccination.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Japanese Encephalitis Vaccine</keyword>
	<keyword>endemic countries</keyword>
	<keyword>to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51</keyword>
</DOC>